Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
FORT LAUDERDALE, Fla., Feb. 28, 2018 -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading provider of patient-centric, clinical data management technology, signed four additional contracts in December 2017, to provide OmniComm’s proprietary TrialOne clinic automation solution to several major hospitals and contract research organizations (CROs) in China.
OmniComm now has a total of 11 TrialOne clients in China, which were all signed since December 2016, when TrialOne made its debut in that market. The deals were sparked by a strategic partnership with Tri-I Biotech (Shanghai) Inc., a market-leading China-based solutions provider to the life sciences sector.
Two years ago, OmniComm established a goal of developing a presence in the Chinese market, and to-date the company’s performance in that sector has exceeded expectations. The expanded footprint in the Asia-Pacific region includes OmniComm’s first contract for TrialMaster® in Japan, along with agreements for the use of TrialOne, TrialMaster and Promasys® in clinical studies.
“Our progression, from formulating a strategic plan two years ago to making very significant progress into the Chinese market today, has been very exciting,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “We continue to work hard on supporting our partner and our clients to ensure they are as proficient and successful as possible.”
As a system that is compliant with global industry standards and best practices for BA/BE studies and Phase I clinical research, TrialOne allows user organizations to ensure the quality and integrity of the data collected and managed during the clinical trial process. TrialOne also enables users to comply with the Chinese FDA’s new regulation and approval process for generic drug production in China. TrialOne’s ability to facilitate users’ compliance with CFDA’s regulations aimed at harmonizing local practices to global standards was also a key factor influencing the adoption of TrialOne.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations (CROs), diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Please visit www.omnicomm.com for more information.
For information about specific deals in China, please visit: http://www.omnicomm.com/blog/early-phase-research-hospitals-and-cros-sign-new-trialone-contracts-in-china
Contact Info
Kuno van der Post, Ph.D.
OmniComm Systems, Inc.
+1.954.473.1254
[email protected]
